{"title":"利奈唑胺致乳酸性酸中毒","authors":"H. Rehman","doi":"10.15197/EJGM.1439","DOIUrl":null,"url":null,"abstract":"Lactic acidosis is a known complication of long-term linezolid therapy. We present a case where lactic acidosis developed only after 2 doses of linezolid. A review of literature revealed only 2 cases in which lactic acidosis developed soon after linezolid treatment was commenced. Both patients had underlying immunocompromising conditions. Our patient, like the previous 2 reports had an underlying immunocompromising condition – acute myeloid leukemia. It seems that linezolid has the propensity of inducing lactic acidosis soon after its commencement in immunocompromised patients.","PeriodicalId":12017,"journal":{"name":"European journal of general medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"37","resultStr":"{\"title\":\"Linezolid-induced Lactic Acidosis\",\"authors\":\"H. Rehman\",\"doi\":\"10.15197/EJGM.1439\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lactic acidosis is a known complication of long-term linezolid therapy. We present a case where lactic acidosis developed only after 2 doses of linezolid. A review of literature revealed only 2 cases in which lactic acidosis developed soon after linezolid treatment was commenced. Both patients had underlying immunocompromising conditions. Our patient, like the previous 2 reports had an underlying immunocompromising condition – acute myeloid leukemia. It seems that linezolid has the propensity of inducing lactic acidosis soon after its commencement in immunocompromised patients.\",\"PeriodicalId\":12017,\"journal\":{\"name\":\"European journal of general medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-04-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"37\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of general medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15197/EJGM.1439\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of general medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15197/EJGM.1439","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Lactic acidosis is a known complication of long-term linezolid therapy. We present a case where lactic acidosis developed only after 2 doses of linezolid. A review of literature revealed only 2 cases in which lactic acidosis developed soon after linezolid treatment was commenced. Both patients had underlying immunocompromising conditions. Our patient, like the previous 2 reports had an underlying immunocompromising condition – acute myeloid leukemia. It seems that linezolid has the propensity of inducing lactic acidosis soon after its commencement in immunocompromised patients.